Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tacrine hydrochloride
Drug ID BADD_D02104
Description A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.
Indications and Usage For the palliative treatment of mild to moderate dementia of the Alzheimer's type.
Marketing Status Discontinued
ATC Code N06DA01
DrugBank ID DB00382
KEGG ID D02068
MeSH ID D013619
PubChem ID 2723754
TTD Drug ID D0E6YQ
NDC Product Code Not Available
Synonyms Tacrine | 9-Amino-1,2,3,4-Tetrahydroacridine | 1,2,3,4-Tetrahydro-9-acridinamine | Tetrahydroaminoacridine | 1,2,3,4-Tetrahydroaminoacridine | Romotal | Tenakrin | THA | Cognex | Tacrine Hydrochloride
Chemical Information
Molecular Formula C13H15ClN2
CAS Registry Number 1684-40-8
SMILES C1CCC2=NC3=CC=CC=C3C(=C2C1)N.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AstheniaCholinesteraseP06276T99799Not Available
DementiaApolipoprotein EP02649T21689Not Available
DiarrhoeaCholinesteraseP06276T99799Not Available
DizzinessCholinesteraseP06276T99799Not Available
HepatotoxicityCytochrome P450 1A2P05177Not AvailableNot Available
VomitingCholinesteraseP06276T99799Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hostility19.05.01.003--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperkeratosis23.01.01.001--
Hyperkinesia17.01.02.008--Not Available
Hypertension24.08.02.001--
Hyperthyroidism14.11.01.011; 05.02.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hyporeflexia17.02.01.003--
Hypotension24.06.03.002--
Hypothyroidism14.11.01.012; 05.02.03.001--
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal obstruction07.13.01.002--Not Available
Kidney infection20.01.09.004; 11.01.14.006--
Labyrinthitis11.01.05.002; 04.04.03.001--Not Available
Leukopenia01.02.02.001--Not Available
Libido increased19.08.03.002; 21.03.02.007--
Lipoma16.18.01.001; 15.09.01.001--Not Available
Lower respiratory tract infection22.07.01.002; 11.01.09.002--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Malignant melanoma16.03.01.001; 23.08.01.001--Not Available
Micturition urgency20.02.02.006--
Migraine24.03.05.003; 17.14.02.001--Not Available
Movement disorder17.01.02.010--Not Available
Muscle twitching15.05.03.005--Not Available
Myalgia15.05.02.001--
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages